Modena, Italy-based Holostem Terapie Avanzate has appointed Dr Richard Jones as its chief executive officer.
Dr Jones moves to the cell and gene therapy specialist from Swedish biotech Akinion Pharmaceuticals, where he had served as chief executive since January last year.
He brings over two decades of industry experience to the position, including from Novartis, where he was vice president and medicines commercialisation leader for haematology and global oncology.
Prior to this, Dr Jones served as vice president, global haematology medicines leader at GlaxoSmithKline, and has also held posts at Genzyme and Shire.
Dr Paolo Chiesi, chairman of the board at Holostem, said: “On behalf of the Holostem board, I am delighted to welcome Richard to the company.
“He brings a unique combination of international and rare disease expertise, crucial for this stage of Holostem’s evolution.
“We look forward to working with Richard on the continued growth of the company’s development and the realisation of the potential of the technology platform.”